Literature DB >> 21441127

Plasma sTWEAK and PTX3: New determinant tools of cardiovascular outcome also in patients with CKD.

Pascal Meier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21441127     DOI： 10.2215/CJN.01490211

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  3 in total

1.  Relationship between plasma pentraxin 3 level and risk of chronic kidney disease in the Korean elderly: the Dong-gu study.

Authors:  Ran Lee; Min-Ho Shin; Hee-Nam Kim; Young-Hoon Lee; Seong-Woo Choi; Hye-Ran Ahn; Sun-Seog Kweon
Journal:  Int Urol Nephrol       Date:  2017-07-21       Impact factor: 2.370

Review 2.  Biology of human pentraxin 3 (PTX3) in acute and chronic kidney disease.

Authors:  Marijn M Speeckaert; Reinhart Speeckaert; Juan J Carrero; Raymond Vanholder; Joris R Delanghe
Journal:  J Clin Immunol       Date:  2013-02-27       Impact factor: 8.317

3.  Serum sTWEAK and FGF-23 Levels in Hemodialysis and Renal Transplant Patients.

Authors:  H Eskandari Naji; A Ghorbanihaghjo; H Argani; S Raeisi; J Safa; A H Alirezaei; N Rashtchizadeh
Journal:  Int J Organ Transplant Med       Date:  2017-05-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.